Vectus Biosystems Limited (ASX:VBS)

Vectus Biosystems Limited announced the appointment of Dr. Tara Speranza as Chief Executive Officer (CEO) and Chief Technology Officer (CTO) effective May 7, 2026. Dr. Speranza, who has been consulting with Vectus since August 2025, brings over 20 years of experience in scientific research, commercial strategy, and capital markets within healthcare and biotechnology sectors. She has served in academia and collaborated with global pharmaceutical firms, contributing to the development of significant therapies. Dr. Speranza's appointment aligns with Vectus' strategic goals, particularly in advancing their lead programme, VB0004, and engaging with strategic partners to enhance shareholder value. Her extensive expertise in scientific and commercial domains, coupled with her experience in capital markets, positions her to lead Vectus in its next development phase. The employment terms include a remuneration package of $150,000 per annum plus superannuation, with performance-based incentives including shares and zero exercise price options tied to share price and operational milestones.